Dichotomoside B



Compound IDCDAMM02217
Common nameDichotomoside B
IUPAC name3-[3-[5-(3-butoxy-3-oxopropyl)-3-methoxy-2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-4-hydroxy-5-methoxyphenyl]propanoic acid
Molecular formulaC30H40O13

Experimental data

Retention time4.75
Adduct[2M+NH4]+
Actual mz1234.53
Theoretical mz1234.53
Error0.14
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score5.2038

Identifiers and class information

Inchi keyCQJZSGNCDIJTLR-ACSYHXPKNA-N
SmilesO=C(O)CCC1=CC(OC)=C(O)C(=C1)C=2C=C(C=C(OC)C2OC3OC(CO)C(O)C(O)C3O)CCC(=O)OCCCC
SuperclassOrganic oxygen compounds
ClassOrganooxygen compounds

Pharmacokinetic properties

Number of descriptor values(#stars)4
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)1
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)20
Number of reactive functional groups (#rtvFG)2
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)608.638
Computed dipole moment(dipole)5.486
Total solvent accessible surface area (SASA)848.859
Hydrophobic component of SASA (FOSA)520.797
Hydrophilic component of SASA (FISA)280.188
Pie component of the SASA (PISA)47.874
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1716.89
Number of hydrogen bond donors (donorHB)6
Number of hydrogen bond acceptors (accptHB)15.5
Free energy of solvation of dipole (dip^2/V)0.0175321
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0447272
Globularity descriptor (glob)0.816878
Predicted polarizability in cubic angstroms (QPpolrz)50.171
Predicted hexadecane/gas partition coefficient (QPlogPC16)17.626
Predicted octanol/gas partition coefficient (QPlogPoct)34.175
Predicted water/gas partition coefficient (QPlogPw)23.637
Predicted octanol/water partition coefficient (QPlogPo/w)1.765
Predicted aqueous solubility (QPlogS)-2.993
Conformation-independent predicted aqueous solubility (CIQPlogS)-5.858
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-2.916
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)5.527
Predicted brain/blood partition coefficient (QPlogBB)-3.441
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)2.284
Predicted skin permeability, log Kp (QPlogKp)-4.595
PM3 calculated ionization potential (IP(ev))8.946
PM3 calculated electron affinity (EA(eV))0.309
Number of likely metabolic reactions (#metab)11
Prediction of binding to human serum albumin (QPlogKhsa)-0.723
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)11.692
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)213.01
Number of nitrogen and oxygen atoms (#NandO)13
Number of violations of Lipinski’s rule of five (RuleOfFive)3
Number of violations of Jorgensen’s rule of three (RuleOfThree)2

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P15692VEGFAVascular endothelial growth factor AT20761SEA
P05230FGF1Acidic fibroblast growth factorT18639SEA
P09038FGF2Basic fibroblast growth factorT31621SEA
O43868SLC28A2Sodium/nucleoside cotransporter 2T94627SEA
P16109SELPP-selectinT10965SEA
P14151SELLLeukocyte adhesion molecule-1T60526SEA
P60568IL2Interleukin-2T61698SEA
Q9NUW8TDP1Tyrosyl-DNA phosphodiesterase 1T33492SEA
P17931LGALS3Galectin-3T72038SEA
P14679TYRTyrosinaseT97035SEA
Q9NZ08ERAP1Endoplasmic reticulum aminopeptidase 1T72849SEA
O00398P2RY10Putative P2Y purinoceptor 10T00488SEA
P05231IL6Interleukin-6T32578SEA
P30837ALDH1B1Acetaldehyde dehydrogenaseT99641SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T20761DI0095Colorectal cancer[ICD-11: 2B91]P15692VEGFA
T20761DI0365Retinopathy[ICD-11: 9B71]P15692VEGFA
T20761DI0430Vascular system developmental anomaly[ICD-11: LA90]P15692VEGFA
T18639DI0081Chronic arterial occlusive disease[ICD-11: BD4Z]P05230FGF1
T18639DI0102Coronary atherosclerosis[ICD-11: BA52]P05230FGF1
T31621DI0005Acne vulgaris[ICD-11: ED80]P09038FGF2
T10965DI0088Circulatory system disease[ICD-11: BE2Z]P16109SELP
T10965DI0381Sickle-cell disorder[ICD-11: 3A51]P16109SELP
T60526DI0037Asthma[ICD-11: CA23]P14151SELL
T60526DI0088Circulatory system disease[ICD-11: BE2Z]P14151SELL
T61698DI0275Multiple sclerosis[ICD-11: 8A40]P60568IL2
T61698DI0361Renal cell carcinoma[ICD-11: 2C90]P60568IL2
T72038DI0190Hypertension[ICD-11: BA00-BA04]P17931LGALS3
T72038DI0199Idiopathic interstitial pneumonitis[ICD-11: CB03]P17931LGALS3
T72038DI0252Melanoma[ICD-11: 2C30]P17931LGALS3
T72038DI0302Non-alcoholic fatty liver disease[ICD-11: DB92]P17931LGALS3
T72038DI0351Psoriasis[ICD-11: EA90]P17931LGALS3
T97035DI0007Acquired hypermelanosis[ICD-11: ED60]P14679TYR
T97035DI0008Acquired hypomelanotic disorder[ICD-11: ED63]P14679TYR
T32578DI0028Anemia[ICD-11: 3A00-3A9Z]P05231IL6
T99641DI0396Substance abuse[ICD-11: 6C40]P30837ALDH1B1

Copyright © 2025